NASDAQ:ALVO Alvotech (ALVO) Stock Price, News & Analysis $3.34 -0.04 (-1.18%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.32 -0.02 (-0.72%) As of 05/22/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Alvotech Stock (NASDAQ:ALVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Alvotech alerts:Sign Up Key Stats Today's Range$3.31▼$3.4450-Day Range$3.11▼$3.8252-Week Range$3.03▼$11.85Volume197,523 shsAverage Volume425,909 shsMarket Capitalization$1.01 billionP/E RatioN/ADividend YieldN/APrice Target$7.60Consensus RatingHold Company Overview Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers. Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara). The company’s lead candidate, AVT02 (a biosimilar to adalimumab), is being developed in collaboration with Teva Pharmaceuticals and has received marketing approval in several regions. Additional programs in late‐stage development aim to replicate therapies used across autoimmune disorders and cancer treatment, underscoring Alvotech’s focus on high‐value therapeutic areas. Headquartered in Reykjavík, Iceland, Alvotech operates state‐of‐the‐art facilities that integrate research, development and large‐scale manufacturing under one roof. The company has also established regulatory and commercial partnerships to support product launches in key markets, including the United States, Europe and select Asia‐Pacific territories. This global footprint enables Alvotech to align its clinical development plans with regional regulatory requirements while optimizing supply chain logistics for commercial distribution. Alvotech’s leadership team is led by Founder and Executive Chairman Robert Wessman, a biopharmaceutical entrepreneur with decades of industry experience. Under his guidance, the company has expanded its scientific capabilities and forged strategic alliances to advance its biosimilar portfolio. Supported by a management team with expertise in biologics development, regulatory affairs and global commercialization, Alvotech is positioned to play a significant role in increasing patient access to affordable biologic therapies.AI Generated. May Contain Errors. Read More Alvotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreALVO MarketRank™: Alvotech scored higher than 67% of companies evaluated by MarketBeat, and ranked 368th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingAlvotech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 2 sell ratings.Upside PotentialAlvotech has a consensus price target of $7.60, representing about 127.5% upside from its current price of $3.34.Amount of Analyst CoverageAlvotech has only been the subject of 4 research reports in the past 90 days.Read more about Alvotech's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth950.00% Earnings GrowthEarnings for Alvotech are expected to grow by 950.00% in the coming year, from $0.02 to $0.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alvotech is -13.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alvotech is -13.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.79% of the float of Alvotech has been sold short.Short Interest Ratio / Days to CoverAlvotech has a short interest ratio ("days to cover") of 5.82.Change versus previous monthShort interest in Alvotech has recently decreased by 12.10%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlvotech does not currently pay a dividend.Dividend GrowthAlvotech does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.21 News SentimentAlvotech has a news sentiment score of -0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Alvotech this week, compared to 8 articles on an average week.Search InterestOnly 2 people have searched for ALVO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alvotech insiders have not sold or bought any company stock.Percentage Held by Insiders0.46% of the stock of Alvotech is held by insiders.Percentage Held by InstitutionsAlvotech has minimal institutional ownership at this time.Read more about Alvotech's insider trading history. Receive ALVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alvotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALVO Stock News HeadlinesAlvotech (NASDAQ:ALVO) Cut to "Sell" at Wall Street ZenMay 23 at 1:28 AM | americanbankingnews.comAlvotech Earnings Call Balances Setbacks and MomentumMay 20 at 4:11 AM | tipranks.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 23 at 1:00 AM | Profits Run (Ad)Alvotech (NASDAQ:ALVO) Receives Average Rating of "Hold" from BrokeragesMay 16, 2026 | americanbankingnews.comAlvotech (ALVO) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comAlvotech Earnings Call Balances Risk and GrowthMay 11, 2026 | theglobeandmail.comAlvotech advances after FDA wraps Iceland plant inspectionMay 11, 2026 | msn.comAlvotech shares rise as FDA completes Reykjavik facility inspectionMay 11, 2026 | msn.comSee More Headlines ALVO Stock Analysis - Frequently Asked Questions How have ALVO shares performed this year? Alvotech's stock was trading at $5.13 at the start of the year. Since then, ALVO shares have decreased by 34.9% and is now trading at $3.34. How were Alvotech's earnings last quarter? Alvotech (NASDAQ:ALVO) issued its earnings results on Tuesday, March, 31st. The company reported ($0.09) earnings per share (EPS) for the quarter. The company earned $105.90 million during the quarter. Alvotech had a negative trailing twelve-month return on equity of 11.92% and a negative net margin of 14.36%. Read the conference call transcript. Who are Alvotech's major shareholders? Top institutional shareholders of Alvotech include Oaktree Capital Management LP (0.08%) and Renaissance Technologies LLC (0.02%). How do I buy shares of Alvotech? Shares of ALVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alvotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alvotech investors own include Micron Technology (MU), Arista Networks (ANET), United Microelectronics (UMC), Weatherford International (WFRD), NVIDIA (NVDA), PACCAR (PCAR) and Axcelis Technologies (ACLS). Company Calendar Last Earnings3/31/2026Today5/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (14m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ALVO's financial health is in the Red zone, according to TradeSmith. ALVO has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALVO Previous SymbolNYSE:ALVO CIK1898416 Webwww.alvotech.com Phone354-422-4500FaxN/AEmployees1,460Year Founded2013Price Target and Rating Average Price Target for Alvotech$7.60 High Price Target$10.00 Low Price Target$4.00 Potential Upside/Downside+127.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.25) Trailing P/E RatioN/A Forward P/E Ratio167.00 P/E GrowthN/ANet Income$27.92 million Net Margins-14.36% Pretax Margin23.25% Return on Equity-11.92% Return on Assets-7.58% Debt Debt-to-Equity RatioN/A Current Ratio1.89 Quick Ratio1.16 Sales & Book Value Annual Sales$588.90 million Price / Sales1.71 Cash Flow$0.22 per share Price / Cash Flow15.51 Book Value($0.94) per share Price / Book-3.55Miscellaneous Outstanding Shares301,810,000Free Float300,418,000Market Cap$1.01 billion OptionableNot Optionable Beta0.21 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ALVO) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alvotech Please log in to your account or sign up in order to add this asset to your watchlist. Share Alvotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
